Madrigalв — Dip

The "dip" was primarily triggered by releasing positive Phase 2b data for its drug efruxifermin in patients with compensated cirrhosis due to MASH (metabolic dysfunction-associated steatohepatitis).

: Following this news, Madrigal shares traded down roughly 5% . Investment Sentiment MadrigalВ Dip

: Evercore ISI explicitly labeled the dip as a Buying Opportunity , maintaining an "Outperform" rating with a price target of $392 . The "dip" was primarily triggered by releasing positive

Investment firms, including and Piper Sandler , maintain a bullish outlook despite the price drop: including and Piper Sandler